Author: [email protected]

TG Therapeutics, Inc. Announces $18.1 Million Underwritten Sale of Common Stock to a Single Institutional Investor

On March 11, 2014 TG Therapeutics announced it has priced an underwritten sale of 2,702,809 shares of its common stock at $6.71 per share, the closing price on March 11, 2014, to JP Morgan Asset Management’s Global Healthcare Fund. Gross proceeds from the sale are expected to be approximately $18.1 million (Press release TG Therapeutics, MAR 11, 2014, View Source [SID:1234500264]). TG Therapeutics intends to use the proceeds from the offering to fund the clinical development of TG-1101 and TGR-1202 and other general corporate purposes. The offering is expected to close on or about March 17, 2014, subject to customary closing conditions.
Michael S. Weiss, the Company’s Executive Chairman and Interim Chief Executive Officer, commented on the transaction, "We are very excited to have consummated this financing with a premier biotechnology investor. The proceeds from the financing and existing cash provide us with funding to support our current and planned clinical programs for the next several years as well as flexibility to opportunistically acquire additional complimentary products or technologies."

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Human medicines European public assessment report (EPAR): Yervoy, ipilimumab, Revision: 4, Authorised

On March 11, 2014 a periodic safety update was reported to have been added to the EPAR for Yervoy (External Source EMA, Bristol-Myers Squibb, MAR 11, 2014, View Source [SID:1234500262]).
A review of cases of anaphylaxis or cytokine release syndrome events identified a total of 6 cases: two of the 6 cases had limited information for assessment. Nevertheless, there have been cases of anaphylactic reactions, resulting in hospitalization in at least one patient; and for which stopping the medication and supportive care was needed in all reported cases. Due to the characteristics of the cases (rapid time to onset and severity of the events) the PRAC considered that anaphylactic reactions should be included in section 4.8 of the SmPC, with a frequency based on clinical trials, i.e. very rare (<0.01% (1/12881)). The package leaflet is updated accordingly. The CHMP agrees with the scientific conclusions made by the PRAC. Commission decision was issued on DEC 18, 2013.

Bayer and Onyx Report Phase 3 Study Results of NEXAVAR� (sorafenib) as Adjuvant Treatment for Patients with Liver Cancer Who Have Undergone Surgery or Local Ablation

On March 11, 2014 Bayer HealthCare Pharmaceuticals and Onyx Pharmaceuticals announced that a Phase 3 trial (NCT00692770) evaluating the investigational use of NEXAVAR (sorafenib) tablets as an adjuvant treatment for patients with hepatocellular carcinoma (HCC), or liver cancer, who had no detectable disease after surgical resection or local ablation, did not meet its primary endpoint of improving recurrence-free survival (Press release Amgen, MAR 11, 2014, View Source;p=RssLanding&cat=news&id=1907747 [SID:1234500257]). The safety findings were consistent with the known profile of sorafenib. Data from this study will be submitted for presentation at an upcoming scientific congress.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Experimental breast cancer drug to be trialled in lung cancer patients

An experimental drug olaparib, originally designed to treat breast cancer, is now to be tested in patients with advanced lung cancer (Press release Cancer Research UK, MAR 11, 2014, View Source [SID:1234500252]).
Olaparib, a PARP inhibitor, will be given after chemotherapy to patients with non-small cell lung cancer (NSCLC) to see if it delays the growth of their tumor. Around half of NSCLCs have faults in one of the ways they repair DNA damage. Research has shown that adding a PARP inhibitor makes it even harder for the cancer to repair this damage. Olaparib is also being tested in phase III trials for ovarian and stomach cancers.
The phase II trial will recruit over 100 people with advanced non-small cell lung cancer at 25 hospitals around the UK. It is funded by Cancer Research UK and AstraZeneca through a National Cancer Research Network initiative and is being co-ordinated by Cancer Research UK’s Wales Cancer Trials Unit at Cardiff University and Velindre NHS Trust in Cardiff.

(Press release, New Amsterdam Sciences, MAR 10, 2014, View Source!news/nws17/B15A676B-EE12-429B-8F67-3D4B19755DBE/new-amsterdam-sciences-secures-research-and-funding-support-from-the-national-institute-of-health [SID:1234505522])

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!